Alder names Paul Cleveland to board
This article was originally published in Scrip
Executive Summary
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, has named Paul B. Cleveland to its board of directors. Cleveland currently serves as president and CEO of Celladon Corporation and previously served as Celladon's president and chief financial officer. He is also a member of the board and chair of the audit committee of Sangamo Biosciences, Inc.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.